Pakistan Pharma: CY24: Improving profitability prospects - By JS Research
Mar 27 2025
JS Global Capital
- We analyse CY24 performance of the listed pharmaceutical sector, using a sample size of nine companies. The year remained positive for the sector, mainly due to stable currency and raw material prices, coupled with the deregulation of non-essential drug pricing, which enabled companies to pass on cost impacts as needed to ensure the availability of key drugs.
- During CY24, our sample companies cumulatively posted a significant topline growth of 20% YoY, reaching Rs297bn, mainly driven by an increase in drug pricing, which supported 9ppts YoY higher gross margins to 35%. Likewise, the bottom line came in at Rs22bn, reflecting a 3x YoY growth.
- On the sequential front, topline growth during 4QCY24 hovered around 27% YoY, with major impact from deregulation, which led to price increases that were more pronounced in 2HCY24. As a result, gross margins remained significantly high, up 11ppts YoY to 39% during the quarter.